LGVN Company Profile and Key Details

Longeveron Inc. generated EPS of -$1.34 over the past year. Five-year average earnings growth is -11.05%. Wall Street analysts project EPS growth of 26.98% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.37. Next year's EPS is expected at $17.77. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $3.00. The high target offers 830.23% upside. The low target suggests 248.84% downside. The mean target is $5.50. This offers 539.53% upside. Longeveron Inc. earnings surprise history is a mixed track record. The quarter that ended March 17, 2026, missed forecasts by -47.62%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include -35.85% in November 12, 2024.

Short-term trend indicators are bullishly aligned (SMA20 5.25%, SMA50 3.91%, SMA200 -35.87%). The stock’s 14-day RSI is 54.23 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.79% below its high and over 17.89% above its low. Average 10-day trading volume of 227.64 thousand shares is below the 3-month average of 6.17 million, indicating normal recent market interest.

Longeveron Inc. (NASDAQ:LGVN) closed at $0.86 USD, gaining $0.01 (1.39%) from the previous close of $0.85. The stock is currently mid-range between its 52-week high and low $0.47 and $1.80. With a market capitalization of about $20.11 million, Longeveron Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.19). Key stats such as the average daily volume over the past year has been around 5.77 million shares, volume is running light vs its 52-week average. Headquartered in Miami, FL, Longeveron Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephen H. Willard, the company employs approximately 25 people and listed since February 12, 2021. Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.

Longeveron Inc. has 19.31 million shares outstanding. The public float is 11.14 million shares, elevated short interest at 4.05% of float. This equals 511.33 thousand shares. The short ratio is 0.69 days. Institutional investors hold 8.17% of the float. Insiders own 14.83%. Hare Joshua holds 721.80 thousand shares, Soffer Rock has 209.03 thousand shares and Soffer Donald M has 153.51 thousand shares.

Longeveron Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.48. This means the shares are trading below this model’s fair value.

Longeveron Inc. trades at a P/E ratio of -0.86, slightly below the S&P 500 average, with a price-to-sales ratio of 16.57 and a price-to-book ratio of 3.44 trading at moderately above to book value. The P/FCF stands at -1.04, also above market averages.

Our AI price prediction model suggests that Longeveron Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.99%, with price expected at $0.88 by May 18, 2026, within a range of $0.75 to $1.01 3-Month Outlook: Projected rise of 99.35%, reaching $1.72 by July 31, 2026, with a range of $1.67 to $1.79. 1-Year Outlook: Projected loss of -46.69%, with price at $0.46 by May 04, 2027, within a range of $0.10 to $0.69.

Longeveron Inc. (NASDAQ:LGVN) shares are flat 4.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Longeveron Inc. trading at a premium to the broader market with a P/E of -0.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.09, suggesting 1069.45% upside. Our AI forecast model points to short-term strength (1.99% over two weeks), a medium-term rise (99.35% over three months), and a longer-term loss (-46.69% over one year), with expected trading ranges indicating moderate volatility.